Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Corgi Genomics & Precision Medicine ETF(GNMX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GNMX
11/06/2026: GNMX (2-star) is a SELL. SELL for 2 days. Simulated Profits (-0.25%). Updated daily EoD!
GNMX provides focused, index-based exposure to companies in the genomics and precision medicine sector. Its primary strength lies in its targeted approach, allowing investors to isolate the growth potential of gene editing and biotechnology. It is best suited as a satellite holding for long-term growth portfolios with high risk tolerance. Investors should be aware of the sector-specific concentration, volatility resulting from R&D reliance, and regulatory risks. Key factors to monitor include clinical trial milestones, industry M&A activity, and interest rate trends affecting growth-stage valuations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets high-growth innovative firms with significant long-term potential. |
| Momentum investor | Strong fit while signal remains positive | The genomic sector often experiences periods of high momentum driven by clinical trial news. |
| Value investor | Weak fit | Many companies in this sector are pre-revenue or trade at high valuation multiples. |
| Dividend/Income investor | Weak fit | Biotechnology firms typically reinvest all earnings, providing zero dividend yield. |
| Low-risk investor | Weak fit | The sector's inherent volatility makes it unsuitable for risk-averse portfolios. |
Investor Profile
Ideal Investor Profile
Growth-oriented investors with a high risk tolerance who seek long-term exposure to disruptive medical innovation.
Suitability
Primarily for long-term investors; not recommended for active short-term traders due to liquidity and volatility.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Genomic stocks are prone to large price swings based on FDA approvals and clinical data. |
| Market risk | Medium / high | The fund is subject to general equity market downturns, particularly in the growth-sensitive biotech space. |
| Concentration | High | The focus on a single industry segment increases risk compared to diversified healthcare funds. |
| Tracking/expense | Medium | Expense ratios are higher than broad index funds due to the specialized nature of the index. |
| Liquidity | Medium | Lower trading volumes for some smaller constituents can impact execution during market stress. |
| Business/sector quality | Medium / high | Investment in early-stage R&D firms entails the risk of complete capital loss on individual companies. |
Risk Analysis
Volatility
GNMX exhibits high historical volatility characteristic of clinical-stage biotech stocks.
Market Risk
The primary risk is the concentration of assets in companies with unproven revenue models and high dependence on R&D outcomes.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Biotechnology and Genomics | 65 | This exposure provides direct access to high-growth firms developing next-generation medical therapies. |
| Industry | Life Sciences Tools & Services | 25 | These companies provide the essential infrastructure and equipment needed for genomic sequencing. |
| Cash/collateral | Cash and Cash Equivalents | 10 | Maintains liquidity for operational needs and potential rebalancing opportunities. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit -0.25% | Avg. Invested days 45 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.